|
Author Year
Country
Score
Research Design
Total Sample Size
|
Methods
|
Outcome
|
|
Hagenbach et al. 2007
Switzerland
PEDro=4
RCT (Phase 3)
N=13
|
Population: SCI (N=15): Age = 29-66 yrs; Gender: males = 11, females = 2; Level of injury: C4-T11; Severity of injury: AIS: A,B,C,D; Type of pain=spastic.
Treatment: In a double blind manner, SCI patients from phase 1 of the study were randomly assigned to either maximum oral THC doses (6 participants) or placebo doses (7 participants) for 6 weeks.
Pain Scale: Self ratings
|
- No significant improvement in pain post SCI was seen compared to placebo on day 8 and 43.
- Individuals in the oral THC group showed no significant difference in mood or attention compared to the placebo group or to baseline.
|
|
Hagenbach et al. 2007
Switzerland
D&B=16
Pre-Post (Phase 1)
N=22
|
Population: SCI (N=15): Age = 29-66 yrs; Gender: males = 11, females = 2; Level of injury: C4-T11; Severity of injury: AIS: A,B,C,D Type of pain=spastic.
Treatment: Patients received 10mg oral THC on day 1. Dose titration began on day 2 until the maximum tolerated dose or treatment aim was achieved and maintained for 6 weeks.
Pain Scale: Self ratings
|
- Significant improvement in pain was seen on day 1 compared to baseline measures (p=0.047).
|
Note: AIS=ASIA Impairment Scale
